ORIGINAL ARTICLE
CD56, CD57, HBME1, CK19, Galectin-3 and p63 immunohistochemical stains in differentiating diagnosis of thyroid benign/malign lesions and NIFTP
1
Department of Pathology, Medical Faculty, Trakya University, Turkey
2
Subdivision of Cytopathology, Department of Pathology, University of Porto, Porto, Portugal
3
Public Health Department, Ankara University Medical School, Ankara, Turkey
4
Department of Endocrinology, Medical Faculty, Trakya University, Turkey
5
Department of General Surgery, Medical Faculty, Trakya University, Turkey
6
Department of Pathology, Luleburgaz State Hospital, Turkey
Submission date: 2019-07-02
Final revision date: 2019-10-29
Acceptance date: 2019-10-29
Publication date: 2020-03-06
Pol J Pathol 2019;70(4):286-294
KEYWORDS
TOPICS
ABSTRACT
Detection of thyroid carcinoma has been steadily increased in the past few decades. After the recognition of NIFTP, also gain importance to differentiate benign tumors (follicular adenoma) from follicular patterned variants of papillary thyroid carcinoma (invasive and infiltrative follicular variant papillary thyroid carcinoma), and low-risk lesions of thyroid (NIFTP).
Follicular patterned proliferations of thyroid still persists as a battle for pathologists. In this study, we aimed to analyze the most commonly used immunohistochemical stains “HBME1, CK19, Galectin-3”, adding the new ones “CD56, CD57, and p63”.
Study groups were; nodular hyperplasia, follicular adenoma, NIFTP, infiltrative follicular variant PTC, classical variant PTC (CVPTC) and follicular carcinoma. Each group consisted of twenty cases. The sections were stained with CD56, CD57, p63, CK19, HBME1 (Mesotel cell), Galectin-3 antibody.
Although the expression of CD56 was high in benign follicular lesions, FC could not be excluded in this group. CD57 was high in malignant follicular group and NIFTP. Interestingly, p63 was found highly expressed in FVPTC, which might be promising to predict invasiveness in follicular group of lesions. CK19, Galectin-3 and HBME1 were found quietly prominent in CVPTC in concordance with the previous reports.
Follicular patterned proliferations of thyroid still persists as a battle for pathologists. In this study, we aimed to analyze the most commonly used immunohistochemical stains “HBME1, CK19, Galectin-3”, adding the new ones “CD56, CD57, and p63”.
Study groups were; nodular hyperplasia, follicular adenoma, NIFTP, infiltrative follicular variant PTC, classical variant PTC (CVPTC) and follicular carcinoma. Each group consisted of twenty cases. The sections were stained with CD56, CD57, p63, CK19, HBME1 (Mesotel cell), Galectin-3 antibody.
Although the expression of CD56 was high in benign follicular lesions, FC could not be excluded in this group. CD57 was high in malignant follicular group and NIFTP. Interestingly, p63 was found highly expressed in FVPTC, which might be promising to predict invasiveness in follicular group of lesions. CK19, Galectin-3 and HBME1 were found quietly prominent in CVPTC in concordance with the previous reports.
REFERENCES (34)
1.
Canberk S, Gunes P, Onenerk M, et al. New Concept of the Encapsulated Follicular Variant of Papillary Thyroid Carcinoma and Its Impact on the Bethesda System for Reporting Thyroid Cytopathology: A Single-Institute Experience. Acta Cytol 2016; 60: 198-204.
2.
Seethala RR, Baloch ZW, Barletta JA, et al. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features: A review for pathologists. Mod Pathol 2018; 31: 39-55.
3.
Nechifor-Boilă A, Cătană R, Loghin A, et al. Diagnostic value of HBME-1, CD56, Galectin-3 and Cytokeratin-19 in papillary thyroid carcinomas and thyroid tumors of uncertain malignant potential. Rom J Morphol Embryol 2014; 55: 49-56.
4.
Alves VAF, Kakudo K, LiVolsi V, et al. Noninvasive Follicular Thyroid Neoplasm With Papillary-Like Nuclear Features (NIFTP): Achieving Better Agreement By Refining Diagnostic Criteria. Clinics (Sao Paulo) 2018; 73: e576.
5.
Hirshoren N, Kaganov K, Weinberger JM, et al. Thyroidectomy Practice After Implementation of the 2015 American Thyroid Association Guidelines on Surgical Options for Patients With Well-Differentiated Thyroid Carcinoma. JAMA Otolaryngol Head Neck Surg 2018; 144: 427-432.
6.
Radu TG, Mogoantă L, Busuioc CJ, et al. Histological and immunohistochemical aspects of papillary thyroid cancer. Rom J Morphol Embryol 2015; 56 (2 Suppl): 789-795.
7.
LiVolsi VA, Baloch ZW. Follicular-patterned tumors of the thyroid: the battle of benign vs. malignant vs. so-called uncertain. Endocr Pathol 2011; 22: 184-189.
8.
Zeromski J, Dworacki G, Jenek J, et al. Protein and mRNA expression of CD56/N-CAM on follicular epithelial cells of the human thyroid. Int J Immunopathol Pharmacol 1999; 12: 23-30.
9.
Zeromski J, Lawniczak M, Galbas K, et al. Expression of CD56/N-CAM antigen and some other adhesion molecules in various human endocrine glands. Folia Histochem Cytobiol 1998; 36: 119-125.
10.
Gratsa A, Rooprai HK, Rogers JP, et al. Correlation of expression of NCAM and GD3 ganglioside to motile behaviour in neoplastic glia. Anticancer Res 1997; 17: 4111-4117.
11.
Fogar P, Basso D, Pasquali C, et al. Neural cell adhesion molecule (N-CAM) in gastrointestinal neoplasias. Anticancer Res 1997; 17: 1227-1230.
12.
El Demellawy D, Nasr A, Alowami S. Application of CD56, P63 and CK19 immunohistochemistry in the diagnosis of papillary carcinoma of the thyroid. Diagn Pathol 2008; 3: 5.
13.
Khan A, Baker SP, Patwardhan NA, et al. CD57 (Leu-7) expression is helpful in diagnosis of the follicular variant of papillary thyroid carcinoma. Virchows Arch 1998; 432: 427-432.
14.
Cheifetz RE, Davis NL, Robinson BW, et al. Differentiation of thyroid neoplasms by evaluating epithelial membrane antigen, Leu-7 antigen, epidermal growth factor receptor, and DNA content. Am J Surg 1994; 167: 531-534.
15.
Ghali VS, Jimenez EJS, Garcia RL. Distribution of Leu-7 antigen (HNK-1) in thyroid tumours: Its usefulness as a diagnostic marker for follicular and papillary carcinomas. Hum Pathol 1992; 23: 21-25.
16.
Loy TS, Darkow GVD, Spollen LE, et al. Immunostaining for Leu-7 in the diagnosis of thyroid carcinoma. Arch Pathol Lab Med 1994; 118: 172-174.
17.
Ostrowski ML, Brown RW, Wheeler TM, et al. Leu-7 immunoreactivity in cytologic specimens of thyroid lesions, with emphasis on follicular neoplasms. Diagn Cytopathol 1995; 12: 297-302.
18.
Nechifor-Boila A, Borda A, Sassolas G, et al. Immunohistochemical markers in the diagnosis of papillary thyroid carcinomas: The promising role of combined immunostaining using HBME-1 and CD56. Pathol Res Pract 2013; 209: 585-592.
19.
Cho H, Kim JY, Oh YL. Diagnostic value of HBME-1, CK19, Galectin 3, and CD56 in the subtypes of follicular variant of papillary thyroid carcinoma. Pathol Int 2018; 68: 605-613.
20.
WHO Classification of Tumours of Endocrine Organs. 4th ed. Rosai J (eds.). IARC, Lyon 2017.
21.
Bryson GJ, Lear D, Williamson R, et al. Detection of the CD56+/CD45- immunophenotype by flow cytometry in neuroendocrine malignancies. J Clin Pathol 2002; 55: 535-537.
22.
Abd El Atti RM, Shash LS. Potential diagnostic utility of CD56 and claudin-1 in papillary thyroid carcinoma and solitary follicular thyroid nodules. J Egypt Natl Canc Inst 2012; 24: 175-184.
23.
Muthusamy S, Azhar Sha S, Abdullah Suhaimi SN, et al. CD56 expression in benign and malignant thyroid lesions. Malays J Pathol 2018; 40: 111-119.
24.
Nasir A, Catalano E, Calafati S, et al. Role of p53, CD44V6 and CD57 in differentiating between benign and malignant follicular neoplasms of the thyroid. In Vivo 2004; 18: 189-195.
25.
Zhu X, Sun T, Lu H, et al. Diagnostic significance of CK19, RET, galectin-3 and HBME-1 expression for papillary thyroid carcinoma. J Clin Pathol 2010; 63: 786-789.
26.
Barroeta JE, Baloch ZW, Lal P, et al. Diagnostic value of differential expression of CK19, Galectin-3, HBME-1, ERK, RET, and p16 in benign and malignant follicular-derived lesions of the thyroid: an immunohistochemical tissue microarray analysis. Endocr Pathol 2006; 17: 225-234.
27.
Huang L, Wang X, Huang X, et al. Diagnostic significance of CK19, galectin-3, CD56, TPO and Ki67 expression and BRAF mutation in papillary thyroid carcinoma. Oncol Lett 2018; 15: 4269-4277.
28.
Gharib H, Papini E, Paschke R, et al.; AACE/AME/ETA Task Force on Thyroid Nodules. American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association Medical guidelines for clinical practice for the diagnosis and management of thyroid nodules: Executive summary of recommendations. Endocr Pract 2010; 16: 468-475.
29.
Barut F, Onak Kandemir N, Bektas S, et al. Universal markers of thyroid malignancies: Galectin-3, HBME-1, and cytokeratin-19. Endocr Pathol 2010; 21: 80-89.
30.
Cheung CC, Ezzat S, Freeman JL, et al. Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod Pathol 2001; 14: 338-342.
31.
Nasr MR, Mukhopadhyay S, Zhang S, et al. Immunohistochemical markers in diagnosis of papillary thyroid carcinoma: Utility of HBME1 combined with CK19 immunostaining. Mod Pathol 2006; 19: 1631-1637.
32.
Saleh HA, Jin B, Barnwell J, et al. Utility of immunohistochemical markers in differentiating benign from malignant follicular-derived thyroid nodules. Diagn Pathol 2010; 5: 9.
33.
Bonzanini M, Amadori PL, Sagramoso C, et al. Expression of cytokeratin 19 and protein p63 in fine needle aspiration biopsy of papillary thyroid carcinoma. Acta Cytol 2008; 52: 541-548.
34.
Ohta M, Ookoshi T, Naiki H, et al. HBME-1 and CD15 immunocytochemistry in the follicular variant of thyroid papillary carcinoma. Pathol Int 2015; 65: 119-125.
Share
RELATED ARTICLE
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
